← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06523504

NCT06523504 Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06523504
Status Recruiting
Phase Phase 1, Phase 2
Sponsor Ruihua Wei
Condition Myopia
Study Type INTERVENTIONAL
Enrollment 410 participants
Start Date 2024-02-01
Primary Completion 2026-03-31

Trial Parameters

Condition Myopia
Sponsor Ruihua Wei
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 410
Sex ALL
Min Age 6 Years
Max Age 12 Years
Start Date 2024-02-01
Completion 2026-03-31
Interventions
DIMSThe 0.02% ATP GroupThe 0.04% ATP Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.

Eligibility Criteria

Inclusion Criteria: * School-age children aged 6 to 12 years (including boundary value) * Children with moderate or high myopia (subjective refraction after cycloplegia: -9.00D≤spherical equivalent (SE)≤-3.00D, with-rule astigmatism (C)≤2.00D, against-rule astigmatism (C)≤1.00D, anisometropia of both eyes≤2.50D) * Binocular best corrected visual acuity (BCVA)≥0.8 (five-point visual acuity 4.9) * Agree with the study scheme and sign the informed consent * Note: if both eyes meet the inclusion criteria, the eye with higher spherical equivalent is the study eye; if one eye meets the inclusion criteria, the eye is the study eye. Exclusion Criteria: * Used or currently using orthokeratology, multifocal contact lenses, defocusing framework lenses, atropine eye drops and other myopia control means in the past month; used red light treatment in the past * Children with obvious strabismus and amblyopia * With congenital eye disease, such as congenital cataract, congenital retinal disease * Seco

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology